« Back
Home /
Resiquimod

Resiquimod

Item no.	HY-13740-500mg
Manufacturer	MedChem Express
CASRN	144875-48-9
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 500 mg 50 mg 5 mg
Category	Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Glucose Homeostasis Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Sachan S, et al. Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken. Vaccine. 2015 Aug 26;33(36):4526-32.\|[2]Brugnolo F, et al. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003 Feb;111(2):380-8.\|[3]Zhou ZX, et al. Immune effects of R848: evidences that suggest an essential role of TLR7/8-induced, Myd88- and NF-κB-dependent signaling in the antiviral immunity of Japanese flounder (Paralichthys olivaceus). Dev Comp Immunol. 2015 Mar;49(1):113-20.\|[4]Maki Yokogawa, et al. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus. Arthritis Rheumatol. 2014 Mar;66(3):694-706. \|[5]Manuel Keppler, et al. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo. Front Immunol. 2023 Jun 20:14:1168252.
Smiles	OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	R848,S28463
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HCV; Toll-like Receptor (TLR)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	314.39
Product Description	Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMF: 50 mg/mL (ultrasonic)\|DMSO: 100 mg/mL (ultrasonic)\|Ethanol: 25 mg/mL (ultrasonic)\|H2O: 0.1 mg/mL (ultrasonic)\|Methanol: 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Immunology/Inflammation
Isoform	TLR7; TLR8
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13740-500mg-safety-datasheet.pdf